13/10/06
2006 3rd quarter: sales up 9%
€ millions 2006 2005 % change Q3 Sales 24.89 22.76 9% France, including overseas dependencies 11.96 10.83 10% Subsidiaries (1) 9.73 8.88 10% Distributors 3.20 3.05...
12/09/06
1st Half Year 2006 : A 14% increase in sales,major R&D efforts: ORALAIR® Grasses within sight
The Board of Directors, meeting on 12 September 2006, under the chairmanship of Albert SAPORTA, approved the consolidated financial statements at 30 June 2006, prepared in accordance with international standards. The...
15/03/06
1st Half Year 2006 : A 14% increase in sales
The Board of Directors, meeting on 12 September 2006, under the chairmanship of Albert SAPORTA, approved the consolidated financial statements at 30 June 2006, prepared in accordance with international standards. The...
12/04/06
1st quarter 2006 :Strong sales growth of 17%
€ millions 2006 Q1 2005 Q1 % growth France 20,66 17,70 +17% Subsidiaries (1) 11,47 9,66 +19% (2) Distributors 3,46 2,94 +18% Total 35,59 30,30 +17%
(1) Germany, Italy, Spain/Portugal, Belgium (2) + 9%...
15/03/06
2005: Further strong growth in profit Oralair study successful
The Board of Directors, meeting on 14 March 2006, under the chairmanship of Albert Saporta, approved the 2005 consolidated financial statements prepared in accordance with international accounting standards.
€millions 2004 ...
09/03/06
Positive results of study recombinant Bet v 1
Successful proof of concept study of recombinant Bet v 1 efficacy in desensitization against birch pollen allergy
Objective: Birch pollen is one of the most frequent cause of Respiratory Allergy in Central Europe, Northern...
13/01/06
2005 sales: +18% (+15% organic). 2005 4th quarter sales: +14% (+10% organic)
(€millions) 2005 2004 % change 4th quarter 33.10 29.05 +14 France & Overseas territories 16.18 13.98 +16 Subsidiaries (1) 13.26 10.55 +26 Distributors (2) 3.66 4.52 -19 Full year ...
